PREVALENCE AND SEVERITY OF POSSIBLE DRUG-DRUG INTERACTIONS AMONG THE GERIATRIC PATIENTS AT AN INDIAN TERTIARY CARE TEACHING HOSPITAL

Ramam Sripada; Suresh Kumar Sv; Devanna N; Kandula Ravindra Reddy

doi:10.22159/ajpcr.2018.v11i11.27775

Authors

Ramam Sripada Research Scholar, Department of Pharmacy Practice, CES College of Pharmacy, Kurnool, Andhra Pradesh, India.
Suresh Kumar Sv Department of Pharmacognosy, CES College of Pharmacy, Kurnool, Andhra Pradesh, India.
Devanna N Director-OTPRI, JNTUA, Anantapur, Andhra Pradesh, India.
Kandula Ravindra Reddy Department of Pharmaceutics, PRRM College of Pharmacy, Kadapa, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i11.27775

Keywords:

Drug-drug interactions, Geriatrics, Polypharmacy

Abstract

Objective: The objective of this study was to study the prevalence and severity of possible drug-drug interactions (DDIs) among the geriatric patients.

Methods: The present study was a retrospective cross-sectional study. Case records of geriatric inpatients from the medical records department were included in the study and the case records of all the remaining age group inpatients were excluded from the study. All the collected cases were subjected to check for the DDIs using the software Micromedex 2.0 and were categorized into minor, moderate, and major based on the severity.

Results: In this study, a total of 85 cases were screened for possible DDIs, and among them, 54 cases were found to be with 179 possible DDIs. The prevalence was observed to be 63.5%. Most of the possible DDIs were found to be with moderate severity (65.4%) followed by major (25.7%). Majority of the possible DDIs were observed in the Department of General Medicine (83.2%) followed by chest and tuberculosis (7.8%).

Conclusion: Majorly, the severity of interactions was found to be moderate in this study. To reduce the DDIs, rationale prescriptions have to be prescribed by considering the risk-benefit ratio. Geriatrics should be prescribed very cautiously because the age-related pharmacokinetics plays a significant role. By taking all the above aspects into consideration, clinical pharmacist should play a crucial role in the prevention and management of DDIs, especially in geriatrics.

Â

Downloads

Download data is not yet available.

References

Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57-65.

Kim HA, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean elderly. PLoS One 2014;9:e98043.

Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: The slone survey. JAMA 2002;287:337-44.

Nolan L, Oâ€™Malley K. Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988;36:142-9.

Doubova Dubova SV, Reyes-Morales H, Torres-Arreola Ldel P, SuÃ¡rez-Ortega M. Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico city. BMC Health Serv Res 2007;7:147.

Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm 2007;3:426 37.

Yanti E, Kristin E, Yasmina A. Potential drug interactions in hypertensive patients in Liwa district hospital, Lampung Barat, Indonesia. Int J Pharm Pharm Sci 2017;9:134-8.

Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: A review. Am J Geriatr Pharmacother 2011;9:364-77.

Vanitha Jyothi N, Bharathi DR, Prakruthi GM. Evaluation of drug-drug interactions in patients of general medicine, ICU and emergency departments at a tertiary care hospital. Int J Curr Pharm Res 2018;10:68 71.

Murthy NV, Krishnaveni K, Freeda RM, Kumar RS. Assessment of potential drugâ€“drug interaction in stroke patients. Int J Pharm Pharm Sci 2016;8:221-4.

Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998;12:485-94.

Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet 2007;370:185-91.

Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol 2007;21:217-30.

Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther 2009;85:86-8.

McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002;36:1331 6.

Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC. Among older persons in the ambulatory setting incidence and preventability of adverse drug events. JAMA 2003;289:1107-16.

Hosia-Randell HM, Muurinen SM, PitkÃ¤lÃ¤ KH. Exposure to potentially inappropriate drugs and drug-drug interactions in elderly nursing home residents in Helsinki, Finland: A cross-sectional study. Drugs Aging 2008;25:683-92.

Dolton MJ, Pont L, Stevens G, McLachlan AJ. Prevalence of potentially harmful drug interactions in older people in Australian aged-care facilities. J Pharm Pract Res 2012;42:33-6.

Rahmawati F, Hidayati N, Rochmah W, Sulaiman SA. Potentiality of drug-drug interactions in hospitalized geriatric patients in a private hospital, Yogyakarta, Indonesia. Asian J Pharm Clin Res 2010;3:191-4.

Ramam S, Kumar SV, Devanna N, Reddy KR. Prevalence and severity of possible drug-drug interactions in the inpatient department of internal medicine. Int J Pharm Clin Res 2016;8:1212-4.